EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neurohumoral Activation in Heart Failure

Antonis A Manolis, Theodora A Manolis, Antonis S Manolis

International Journal of Molecular Sciences · 23.10.2023 · 24 (20) · 15472

DOI: 10.3390/ijms242015472 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.10.2023. Verfasst von Antonis A Manolis und 2 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Cardiology, Evagelismos Hospital, 106 76 Athens, Greece. Hauptthemen laut MEDLINE: Neprilysin, Heart Failure. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with heart failure (HF), the neuroendocrine systems of the sympathetic nervous system (SNS), the renin–angiotensin–aldosterone system (RAAS) and the arginine vasopressin (AVP) system, are activated to various degrees producing often-observed tachycardia and concomitant increased systemic vascular resistance. Furthermore, sustained neurohormonal activation plays a key role in the progression of HF and may be responsible for the pathogenetic mechanisms leading to the perpetuation of the pathophysiology and worsening of the HF signs and symptoms. There are biomarkers of activation of these neurohormonal pathways, such as the natriuretic peptides, catecholamine levels and neprilysin and various newer ones, which may be employed to better understand the mechanisms of HF drugs and also aid in defining the subgroups of patients who might benefit from specific therapies, irrespective of the degree of left ventricular dysfunction. These therapies are directed against these neurohumoral systems (neurohumoral antagonists) and classically comprise beta blockers, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers and vaptans. Recently, the RAAS blockade has been refined by the introduction of the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan, which combines the RAAS inhibition and neprilysin blocking, enhancing the actions of natriuretic peptides. All these issues relating to the neurohumoral activation in HF are herein reviewed, and the underlying mechanisms are pictorially illustrated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeprilysinHeart FailureHumansTetrazolesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsDrug CombinationsRenin-Angiotensin SystemNatriuretic PeptidesAminobutyratesBiphenyl Compounds

Stichwörter der Autor:innen

angiotensin receptor blockerangiotensin-converting enzyme inhibitorbeta blockerneprilysin inhibitorsneurohormonal activityneurohumoral activation

Substanzen

NeprilysinTetrazolesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsDrug CombinationsNatriuretic PeptidesAminobutyratesBiphenyl Compounds

Autor:innen und Institutionen

  • First Department of Cardiology, Evagelismos Hospital, 106 76 Athens, Greece.
  • Department of Psychiatry, Aiginiteio University Hospital, 115 28 Athens, Greece.
  • First Department of Cardiology, Ippokrateio University Hospital, 115 27 Athens, Greece.

Zitieren

APA

Manolis, A. A., Manolis, T. A., & Manolis, A. S. (2023). Neurohumoral Activation in Heart Failure. International Journal of Molecular Sciences, 24(20), 15472. https://doi.org/10.3390/ijms242015472

Vancouver

Manolis AA, Manolis TA, Manolis AS. Neurohumoral Activation in Heart Failure. International Journal of Molecular Sciences. 2023;24(20):15472. doi:10.3390/ijms242015472

BibTeX
@article{Manolis2023,
  author = {Manolis, Antonis A and Manolis, Theodora A and Manolis, Antonis S},
  title = {Neurohumoral Activation in Heart Failure},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {20},
  pages = {15472},
  doi = {10.3390/ijms242015472}
}
Kostenlos starten →